About Us Services Careers FAQ Contact Us 0
Home Healthcare IT Anti-VEGF Therapeutics Market Size & Share forecast till 2031
Anti-VEGF Therapeutics Market

Anti-VEGF Therapeutics Market Size, Share & Trends Analysis Report By Products (Eylea, Lucentis, Beovu), By Disease (Macular Edema, Diabetic Retinopathy, Retinal Vein Occlusion, Age-related Macular Degeneration) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2023-2031

Report Code: SRHI54734DR
Author : Straits Research
Buy Now
File Formats

Table Of Content

  1. Executive Summary
    1. Research Objectives
    2. Limitations & Assumptions
    3. Market Scope & Segmentation
    4. Currency & Pricing Considered
    1. Emerging Regions / Countries
    2. Emerging Companies
    3. Emerging Applications / End Use
    1. Drivers
    2. Market Warning Factors
    3. Latest Macro Economic Indicators
    4. Geopolitical Impact
    5. Technology Factors
    1. Porters Five Forces Analysis
    2. Value Chain Analysis
    1. North America
    2. Europe
    3. APAC
    4. Middle East and Africa
    5. LATAM
  2. ESG Trends
    1. Global Anti-VEGF Therapeutics Market Introduction
    2. By Products
      1. Introduction
        1. Products By Value
      2. Eylea
        1. By Value
      3. Lucentis
        1. By Value
      4. Beovu
        1. By Value
    3. By Disease
      1. Introduction
        1. Disease By Value
      2. Macular Edema
        1. By Value
      3. Diabetic Retinopathy
        1. By Value
      4. Retinal Vein Occlusion
        1. By Value
      5. Age-related Macular Degeneration
        1. By Value
    1. Introduction
    2. By Products
      1. Introduction
        1. Products By Value
      2. Eylea
        1. By Value
      3. Lucentis
        1. By Value
      4. Beovu
        1. By Value
    3. By Disease
      1. Introduction
        1. Disease By Value
      2. Macular Edema
        1. By Value
      3. Diabetic Retinopathy
        1. By Value
      4. Retinal Vein Occlusion
        1. By Value
      5. Age-related Macular Degeneration
        1. By Value
    4. U.S.
      1. By Products
        1. Introduction
          1. Products By Value
        2. Eylea
          1. By Value
        3. Lucentis
          1. By Value
        4. Beovu
          1. By Value
      2. By Disease
        1. Introduction
          1. Disease By Value
        2. Macular Edema
          1. By Value
        3. Diabetic Retinopathy
          1. By Value
        4. Retinal Vein Occlusion
          1. By Value
        5. Age-related Macular Degeneration
          1. By Value
    5. Canada
    1. Introduction
    2. By Products
      1. Introduction
        1. Products By Value
      2. Eylea
        1. By Value
      3. Lucentis
        1. By Value
      4. Beovu
        1. By Value
    3. By Disease
      1. Introduction
        1. Disease By Value
      2. Macular Edema
        1. By Value
      3. Diabetic Retinopathy
        1. By Value
      4. Retinal Vein Occlusion
        1. By Value
      5. Age-related Macular Degeneration
        1. By Value
    4. U.K.
      1. By Products
        1. Introduction
          1. Products By Value
        2. Eylea
          1. By Value
        3. Lucentis
          1. By Value
        4. Beovu
          1. By Value
      2. By Disease
        1. Introduction
          1. Disease By Value
        2. Macular Edema
          1. By Value
        3. Diabetic Retinopathy
          1. By Value
        4. Retinal Vein Occlusion
          1. By Value
        5. Age-related Macular Degeneration
          1. By Value
    5. Germany
    6. France
    7. Spain
    8. Italy
    9. Russia
    10. Nordic
    11. Benelux
    12. Rest of Europe
    1. Introduction
    2. By Products
      1. Introduction
        1. Products By Value
      2. Eylea
        1. By Value
      3. Lucentis
        1. By Value
      4. Beovu
        1. By Value
    3. By Disease
      1. Introduction
        1. Disease By Value
      2. Macular Edema
        1. By Value
      3. Diabetic Retinopathy
        1. By Value
      4. Retinal Vein Occlusion
        1. By Value
      5. Age-related Macular Degeneration
        1. By Value
    4. China
      1. By Products
        1. Introduction
          1. Products By Value
        2. Eylea
          1. By Value
        3. Lucentis
          1. By Value
        4. Beovu
          1. By Value
      2. By Disease
        1. Introduction
          1. Disease By Value
        2. Macular Edema
          1. By Value
        3. Diabetic Retinopathy
          1. By Value
        4. Retinal Vein Occlusion
          1. By Value
        5. Age-related Macular Degeneration
          1. By Value
    5. Korea
    6. Japan
    7. India
    8. Australia
    9. Taiwan
    10. South East Asia
    11. Rest of Asia-Pacific
    1. Introduction
    2. By Products
      1. Introduction
        1. Products By Value
      2. Eylea
        1. By Value
      3. Lucentis
        1. By Value
      4. Beovu
        1. By Value
    3. By Disease
      1. Introduction
        1. Disease By Value
      2. Macular Edema
        1. By Value
      3. Diabetic Retinopathy
        1. By Value
      4. Retinal Vein Occlusion
        1. By Value
      5. Age-related Macular Degeneration
        1. By Value
    4. UAE
      1. By Products
        1. Introduction
          1. Products By Value
        2. Eylea
          1. By Value
        3. Lucentis
          1. By Value
        4. Beovu
          1. By Value
      2. By Disease
        1. Introduction
          1. Disease By Value
        2. Macular Edema
          1. By Value
        3. Diabetic Retinopathy
          1. By Value
        4. Retinal Vein Occlusion
          1. By Value
        5. Age-related Macular Degeneration
          1. By Value
    5. Turkey
    6. Saudi Arabia
    7. South Africa
    8. Egypt
    9. Nigeria
    10. Rest of MEA
    1. Introduction
    2. By Products
      1. Introduction
        1. Products By Value
      2. Eylea
        1. By Value
      3. Lucentis
        1. By Value
      4. Beovu
        1. By Value
    3. By Disease
      1. Introduction
        1. Disease By Value
      2. Macular Edema
        1. By Value
      3. Diabetic Retinopathy
        1. By Value
      4. Retinal Vein Occlusion
        1. By Value
      5. Age-related Macular Degeneration
        1. By Value
    4. Brazil
      1. By Products
        1. Introduction
          1. Products By Value
        2. Eylea
          1. By Value
        3. Lucentis
          1. By Value
        4. Beovu
          1. By Value
      2. By Disease
        1. Introduction
          1. Disease By Value
        2. Macular Edema
          1. By Value
        3. Diabetic Retinopathy
          1. By Value
        4. Retinal Vein Occlusion
          1. By Value
        5. Age-related Macular Degeneration
          1. By Value
    5. Mexico
    6. Argentina
    7. Chile
    8. Colombia
    9. Rest of LATAM
    1. Anti-VEGF Therapeutics Market Share By Players
    2. M&A Agreements & Collaboration Analysis
    1. Regeneron Pharmaceuticals, Inc.
      1. Overview
      2. Business Information
      3. Revenue
      4. ASP
      5. SWOT Analysis
      6. Recent Developments
    2. Bayer AG
    3. F. Hoffmann-La Roche Ltd
    4. Biogen
    5. Pfizer, Inc.
    6. Coherus BioSciences
    7. Amgen, Inc.
    8. Bausch Health Companies, Inc.
    9. Viatris, Inc.
    10. Novartis AG
    1. Research Data
      1. Secondary Data
        1. Major secondary sources
        2. Key data from secondary sources
      2. Primary Data
        1. Key data from primary sources
        2. Breakdown of primaries
      3. Secondary And Primary Research
        1. Key industry insights
    2. Market Size Estimation
      1. Bottom-Up Approach
      2. Top-Down Approach
      3. Market Projection
    3. Research Assumptions
      1. Assumptions
    4. Limitations
    5. Risk Assessment
    1. Discussion Guide
    2. Customization Options
    3. Related Reports
  3. Disclaimer

Related Reports

Global Report
Anti-Inflammatory Therapeutics Market Size The global anti-inflammatory therapeutics market size was valued at USD 111.78 billion in 2024 and is projected to grow from USD 115.25 billion in 2025 to reach USD 152.78 million b
Buy Now
Global Report
Market Overview The global autoimmune therapeutics market size was valued at USD 71.46 billion in 2024. It is estimated to reach USD 117.43 billion by 2032, growing at a CAGR of 5.69% during the forecast period (2024–2032). The global market i
Buy Now
Global Report
The global hepatitis B therapeutics market size was valued at USD 4.15 billion in 2023. It is estimated to reach USD 5.73 billion by 2032, growing at a CAGR of 3.65% during the forecast period (2024–2032). In the past few years, the rising glob
Buy Now
Global Report
Melanoma Therapeutics Market Size The global melanoma therapeutics market size was valued at USD 8.65 billion in 2023. It is projected to reach USD 19.87 billion by 2032, growing at a CAGR of 10.80% during the forecast period (2024–2032). Mela
Buy Now
Global Report
Peptide Therapeutics Market Size & Trends The global peptide therapeutics market size was valued at USD 45.43 billion in 2023. It is projected to reach from USD 48.11 billion in 2025 to USD 76.11 billion by 2033, growing at a CAGR
Buy Now

Purchase Benefits

  • Eligible for a free updated report next year
  • Completely customizable scope
  • 30% discount on your next purchase
  • Dedicated account manager
  • Query resolution within 24 hours
  • Permission to print the report

We are featured on :

www.straitsresearch.com
© Copyright 2025. All rights Reserved.